You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.
Please do not reply to this message.
On February 24, 2011, FDA updated the Viracept (nelfinavir) label to include drug-drug interaction information between nelfinavir and wafarin.
Table 11 (Established and Other Potentially Significant Drug Interactions) of the Precautions section of the label was changed to add the following:
Coadministration of wafarin and Viracept may affect concentrations of wafarin. It is recommended that the INR (international normalized ratio) be monitored carefully during treatment with Viracept, especially when commencing therapy.
The complete, revised label will be posted soon at Drugs@FDA
Richard Klein
Office of Special Health Issues
Food and Drug Administration
Kimberly Struble
Division of Antiviral Drug Products
Food and Drug Administration
Manage your FDA Subscriptions:
- Update your preferences or unsubscribe
- Questions about this service? support@xxxxxxxxxxxxxxx
- Other inquiries? webmail@xxxxxxxxxx
U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420
